Adjuvant discovery for vaccines against West Nile Virus and Influenza

西尼罗河病毒和流感疫苗的佐剂发现

• 批准号: 9536539
• 负责人: HERMAN STAATS
• 金额: $ 151.18万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2018-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9536539
• 关键词: Adjuvant; Animal Model; Cells; Contractor; Contracts; Emerging Communicable Diseases; Formulation; Human; In Vitro; Influenza; Lead; Libraries; National Institute of Allergy and Infectious Disease; Pharmaceutical Chemistry; Research; Signal Pathway; Structure-Activity Relationship; Study models; Testing; Vaccine Adjuvant; Vaccines; Validation; West Nile virus; Work; high throughput screening; human disease; in vivo; mast cell; novel; pathogen; programs; receptor; vaccine candidate; vaccine discovery

The Adjuvant Discovery Program supports the early stage discovery and initial characterization of novel adjuvant candidates for vaccines. The research must include (1) identification of novel adjuvant candidates through high throughput screening (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates work through and the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model. Projects must include animal model studies to test the adjuvant candidates with vaccines against: A) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens http://www.niaid.nih.gov/topics/emerging/pages/default.aspx), or B) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens as well as one or more other (non-HIV) pathogens relevant to human disease

辅助发现计划支持疫苗新型辅助候选物的早期发现和初始表征。该研究必须包括（1）通过高吞吐量筛选（HTS）方法和验证，导致化合物刺激人类细胞的新佐剂候选者； （2）确定精选铅化合物的作用机理，包括鉴定受体辅助候选者的作用以及它们激活的细胞信号传导途径； （3）在结构活性关系（SAR）研究的指导下，通过制定和药物化学优化铅佐剂候选物； （4）在动物模型中，铅化合物作为疫苗佐剂的功效验证。 项目必须包括动物模型研究，以测试辅助候选疫苗的反对： a）一个或多个niaid出现和重新出现感染病病原体 b）一种或多种尼亚德（NIAID